Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[esi23]

Email received yesterday. We’re in good shape.


As a follow-up to your email, attached are the following documents: (1) press release announcing our transaction with Nostrum, dated May 28, 2020, (2) our new Gene Biotherapeutics Investor Look Book, and (3) our Form 8-K submission (including exhibits, referenced therein) as filed with the Securities and Exchange Commission (“SEC”) on May 21, 2020. Following completion of the transaction, as noted in our attached Form 8-K SEC submission, we reported to the SEC that it is our plan to bring our SEC compliance up to date, a process that we are currently working on. With this complete, we plan to uplist out stock trading from OTC-PINK to OTCQB. This is an important current focus of our efforts.

In addition, we are focused on initiating the commercial manufacture of our Ad5FGF-4 product candidate and we are developing plans to begin our FDA-cleared AFFIRM Phase 3 (fast track) clinical study to evaluate the definitive safety and efficacy of our product candidate, as a one-time treatment for patients with refractory angina due to advanced coronary disease. For more information about our planned Phase 3 clinical study, please visit our web site www.MyRefractoryAngina.com

We appreciate your investment and patience during the transition period and the new realities of a COVID-19 world that we now all find ourselves living within. Please stay safe.

Regards,

Chris Reinhard